These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23132391)

  • 1. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
    Beuselinck B; Wolter P; Karadimou A; Elaidi R; Dumez H; Rogiers A; Van Cann T; Willems L; Body JJ; Berkers J; Van Poppel H; Lerut E; Debruyne P; Paridaens R; Schöffski P
    Br J Cancer; 2012 Nov; 107(10):1665-71. PubMed ID: 23132391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
    McKay RR; Lin X; Perkins JJ; Heng DY; Simantov R; Choueiri TK
    Eur Urol; 2014 Sep; 66(3):502-9. PubMed ID: 24613250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.
    Keizman D; Ish-Shalom M; Pili R; Hammers H; Eisenberger MA; Sinibaldi V; Boursi B; Maimon N; Gottfried M; Hayat H; Peer A; Kovel S; Sella A; Berger R; Carducci MA
    Eur J Cancer; 2012 May; 48(7):1031-7. PubMed ID: 22409947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
    Calvani N; Morelli F; Chiuri V; Gnoni A; Scavelli C; Fedele P; Orlando L; Maiello E; Lorusso V; Cinieri S
    Med Oncol; 2013; 30(2):578. PubMed ID: 23613183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
    Vrdoljak E; Rini B; Schmidinger M; Omrčen T; Torday L; Szczylik C; Sella A
    Anticancer Drugs; 2013 Jun; 24(5):431-40. PubMed ID: 23511427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
    Lee JL; Park I; Park K; Park S; Ahn Y; Ahn JH; Kim TW; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):687-93. PubMed ID: 22237457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
    Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
    Poprach A; Pavlik T; Melichar B; Kubackova K; Bortlicek Z; Svoboda M; Lakomy R; Vyzula R; Kiss I; Dusek L; Buchler T;
    Urol Oncol; 2014 May; 32(4):488-95. PubMed ID: 24321257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.
    Buchler T; Klapka R; Melichar B; Brabec P; Dusek L; Vyzula R; Abrahamova J
    Ann Oncol; 2012 Feb; 23(2):395-401. PubMed ID: 21536664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
    Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
    J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
    Herrmann E; Marschner N; Grimm MO; Ohlmann CH; Hutzschenreuter U; Overkamp F; Groschek M; Blumenstengel K; Pühse G; Steiner T
    World J Urol; 2011 Jun; 29(3):361-6. PubMed ID: 21461939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
    Eichelberg C; Heuer R; Chun FK; Hinrichs K; Zacharias M; Huland H; Heinzer H
    Eur Urol; 2008 Dec; 54(6):1373-8. PubMed ID: 18692304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature.
    Fusco V; Porta C; Saia G; Paglino C; Bettini G; Scoletta M; Bonacina R; Vescovi P; Merigo E; Lo Re G; Guglielmini P; Di Fede O; Campisi G; Bedogni A
    Clin Genitourin Cancer; 2015 Aug; 13(4):287-294. PubMed ID: 25586958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.
    Bozas G; Roy A; Ramasamy V; Maraveyas A
    Onkologie; 2010; 33(6):321-3. PubMed ID: 20523097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
    Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
    J Urol; 2016 Nov; 196(5):1363-1370. PubMed ID: 27288695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.
    Kontovinis L; Laschos K; Karadimou A; Andreadis C; Bamias A; Paraskevopoulos P; Dimopoulos M; Papazisis K
    Med Oncol; 2012 Jun; 29(2):750-4. PubMed ID: 21279702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?
    Calvani N; Morelli F; Leo S; Orlando L; Lombardi L; Gnoni A; Cinefra M; Maiello E; Lorusso V; Cinieri S
    Med Oncol; 2012 Sep; 29(3):1908-13. PubMed ID: 21858552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.